Cutera Inc   (CUTR)
Other Ticker:  
Price: $16.6400 $-0.19 -1.129%
Day's High: $16.99 Week Perf: -3.98 %
Day's Low: $ 16.40 30 Day Perf: -24.19 %
Volume (M): 400 52 Wk High: $ 54.04
Volume (M$): $ 6,663 52 Wk Avg: $37.92
Open: $16.64 52 Wk Low: $13.21

 Market Capitalization (Millions $) 329
 Shares Outstanding (Millions) 20
 Employees 402
 Revenues (TTM) (Millions $) 249
 Net Income (TTM) (Millions $) -92
 Cash Flow (TTM) (Millions $) 109
 Capital Exp. (TTM) (Millions $) 29

Cutera Inc
Cutera Inc is a leading global provider of aesthetic medical technology solutions for skin rejuvenation, hair removal, body sculpting, and other cosmetic procedures. The company was founded in 1998 and is headquartered in Brisbane, California, USA. Cutera Inc's innovative technologies and products are used by dermatologists, plastic surgeons, and medical spas worldwide.

The company's technology offerings include laser and other light-based devices, radiofrequency generators, and other medical equipment. Cutera's products are designed to be versatile, user-friendly, and safe, providing physicians with the flexibility they need to customize treatments for their patients' unique needs.

Cutera's flagship product line is the enlighten laser platform, which is used for skin rejuvenation, tattoo removal, and pigmented lesion treatment. The platform features picosecond and nanosecond pulse durations, as well as multiple wavelengths that allow physicians to precisely target various skin types and conditions.

Another key product line is the excel V laser, which is optimized for the treatment of vascular and pigmented lesions. The laser uses a unique combination of wavelengths to target both superficial and deep blood vessels, as well as unwanted pigmentation caused by sun damage, aging, and other factors.

In addition to its laser and light-based technology solutions, Cutera also offers devices for body sculpting and hair removal. The truSculpt system uses radiofrequency energy to target fat cells and contour the body, while the xeo platform provides a comprehensive solution for all hair removal needs.

Cutera has a strong reputation for innovation and quality, and the company's products have been recognized with numerous industry awards and accolades. The company's commitment to research and development has resulted in a robust pipeline of new products and technologies, ensuring that Cutera will continue to be a leader in the aesthetic medical technology industry for years to come.

   Company Address: 3240 Bayshore Blvd. Brisbane 94005 CA
   Company Phone Number: 657-5500   Stock Exchange / Ticker: NASDAQ CUTR
   CUTR is expected to report next financial results on August 07, 2023.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Delcath Systems Inc

Delcath Systems Inc announced the deficit has been cut back remarkably, over the January to March 31 2023 period

Investors, get ready to rejoice! Delcath Systems Inc has delivered some impressive results for the first quarter of 2023. The company reported a whopping 57.937% revenue growth to $0.60 million, which has effectively helped to bring down losses to $-0.77 per share. This is a significant improvement from the $-1.00 per share loss reported in the same quarter last year.
Despite a decline in revenue in Q4, it's worth noting that the company managed to improve its EPS from $-0.88 to $-0.77 per share in the most recent quarter. It's always a good indication when a company is able to cut losses and improve profitability.

Haemonetics Corporation

Breathtaking financial reporting period by at the Haemonetics Corporation during the February to April 01 2023 span

Investors in Haemonetics Corporation can expect solid growth and increased earnings based on the company's fiscal fourth quarter 2023 financial results. The medical equipment and supplies company reported an impressive 71.13% increase in income per share to $0.77 compared to the previous year, while revenues grew by 31.706% to $342.13 million.
The company's net earnings also saw a healthy increase of 69.37% to $39.348 million. Although operating margin fell to 13.54%, the net margin actually improved to 11.5%. Operating earnings, however, only improved by 29.97% to $46.336 million.

T2 Biosystems Inc

Extremely challenging financial reporting period for T2 Biosystems Inc during the financial period ending March 31 2023

While the stock market can be a turbulent place, there is one company that has had a rough start to 2023. T2 Biosystems Inc recently reported a substantial decrease in revenue, a net loss per share expansion, and a significant drop in sequential revenue, causing some investors to worry.
But let's take a closer look at what these numbers actually mean. While the Mar 31 2023 report was certainly a disappointment, it's important to remember that these are just one quarter's worth of financials. There are always ups and downs in the stock market, and companies often experience setbacks before bouncing back stronger than ever.

H Cyte Inc

The revenue are the similar like a year prior at the Medical Equipment and Supplies company over the January to March 31 2023 span

H Cyte Inc is a company involved in the developing and commercialization of medical therapeutics, specifically in the field of regenerative medicine. The company's focus is on developing therapies for joint and spine-related conditions. The company is headquartered in California and began trading on the NASDAQ Global Market in February 2022 under the ticker symbol HCYT.
In the first quarter of 2023, H Cyte Inc reported that its net deficit had expanded to $-3.38 per share, compared to $0.00 per share in the same period of the previous year. However, the company's EPS improved to $-5.08 per share from the previous reporting season. In terms of revenue, the company's earnings remained unchanged at $0.00 million from the previous year's reporting season and sequentially. The company also reported a net deficit of $-2.090 million in the first quarter of 2023, compared to a deficit of $-3.892 million in the same period of the previous year.

Therapeutic Solutions International Inc

Severe hit for Therapeutic Solutions International Inc all along the financial span ending March 31 2023

Therapeutic Solutions International Inc, a pharmaceutical company, recently published its fiscal interval report ending on March 31, 2023. The report indicated that the company was able to maintain balanced books, showing no earnings or losses per share. This is the same as the previous fiscal year, but an improvement from the previous reporting period.
The company's revenue, on the other hand, decreased by 72.764% from $0.08 million in the comparative period to $0.02 million. However, sequentially, there was a significant increase of 169.53% from $0.01 million. This indicates that the company's financial performance has been unstable overall.


Cutera Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071